Chemotherapy and FDA - Pharmacy Technician Pulse

FDA Expedites Durvalumab Review for Resectable Early-Stage Gastric, Gastroesophageal Cancers

Pharmacy Times

JULY 28, 2025

Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.

Chemotherapy

Chemotherapy FDA

What will shape the Pharma landscape in Q3 2025?

European Pharmaceutical Review

JULY 24, 2025

Key influences include late-stage clinical trial results and regulatory decisions by the US Food and Drug Administration (FDA). In 2021, the FDA first approved the long-acting somatropin prodrug for children aged one year and over with paediatric growth hormone deficiency (GHD) who weigh at least 25.4 pounds.

Chemotherapy

Chemotherapy FDA

Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use

Drug Topics

JULY 14, 2025

Often those very high-end medicines are for very few people.

Immunization

Immunization Specialty Pharmacies Compounding Independent Pharmacies

With ADCs on the rise, drugmakers embrace a new oncology pillar

PharmaVoice

JUNE 6, 2025

The first one approved by the FDA — Mylotarg from Pfizer subsidiary Wyeth for acute leukemia — came to market in 2000. Now, 15 different molecules have been approved by the FDA. At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug.

Chemotherapy

Chemotherapy FDA

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

A recent draft from the FDA provides valuable insight. What will the future hold for clinical research?

FDA

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

Pharmacy Times

AUGUST 13, 2025

As supported by the ECHELON-3 data, this combination fills a critical gap in the treatment landscape and is well aligned with current goals to provide outpatient, targeted, and chemotherapy-free options for challenging hematologic malignancies. Additionally, pharmacists can empower patients to be involved in their treatment plan.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Immunization Compounding Compounding Pharmacies

TAR-200 Clears Tumors in 82% of Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Pharmacy Times

AUGUST 13, 2025

Low- and intermediate-risk patients typically receive transurethral resection of bladder tumor with a single dose of perioperative intravesical chemotherapy. And it appears that having the chemotherapy released slowly over weeks rather than in just a few hours is a much more effective approach.” 3 REFERENCES 1. Pharmacy Times.

Compounding Pharmacies

Compounding Pharmacies Compounding Immunization Chemotherapy

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

JULY 8, 2025

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer. The FDA approved the first MEK inhibitor, a melanoma drug from Novartis, in 2013.

Immunization

Immunization Chemotherapy Insurance Packaging

Ondansetron (Zofran) alternatives: What can I take instead?

The Checkup by Singlecare

AUGUST 7, 2025

Food and Drug Administration (FDA) to prevent nausea and vomiting. but the generic version, ondansetron, is commonly prescribed for patients undergoing cancer treatments such as chemotherapy or radiation, or those who have recently undergone surgery. Aprepitant (Emend) is another, typically used for chemotherapy nausea.

Chemotherapy

Chemotherapy Labelling Insurance Dosage

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

JULY 16, 2025

14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization Chemotherapy

Pharmacist’s Role Expands in the Era of Cannabis Rescheduling

Drug Topics

AUGUST 12, 2025

1 The FDA recommended that the US Drug Enforcement Administration (DEA) move medical marijuana from Schedule I to Schedule III. 2 This determination was based on the FDA’s evaluation of abuse potential, dependency, and accepted medical use for marijuana. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting.

Specialty Pharmacies

Specialty Pharmacies Patient Care Independent Pharmacies Compounding

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Pharmacy Times

JUNE 9, 2025

SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. 1,2 Nivolumab and chemotherapy is a standard of care option for resectable non-small cell lung cancer.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Specialty Pharmacies

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

JUNE 27, 2025

SHOW MORE The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma. The FDA’s review of acalabrutinib was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence that enables concurrent submission and review of oncology drugs across international regulatory agencies.

FDA

FDA Compounding Pharmacies Immunization Chemotherapy

Zongertinib Approved by FDA for Patients With Nonsquamous NSCLC With HER2 TKD Mutations

Pharmacy Times

AUGUST 8, 2025

The FDA's accelerated approval of zongertinib marks a significant advancement for patients with HER2-mutated NSCLC, offering a new treatment option. 1,2 The FDA approval is supported by data from this trial, where zongertinib demonstrated clinically meaningful capabilities in eliciting deep, durable responses.

FDA

FDA Compounding Pharmacies Hospitals Immunization

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. N Engl J Med. 2019;380:2020-2030. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

JUNE 18, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.

Immunization

Immunization Compounding Pharmacies Hospitals Chemotherapy

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

The Orange Book is the reference, and it allows the FDA to declare something [to be] therapeutically equivalent. The FDA Approval Process Within the FDA approval process, the 505(b)(1) new drug application (NDA) submission pathway is the pathway by which new drugs are able to seek approval.

FDA

FDA Compounding Pharmacies Dosage Hospitals

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Pharmacy Times

JUNE 11, 2025

Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.

Specialty Pharmacies

Specialty Pharmacies Compounding Pharmacies Immunization Chemotherapy

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Pharmacy Times

JUNE 12, 2025

The FDA approval process for biologics is lengthier compared with biosimilars. Darkow explained that this is because the FDA mandated that biosimilars must have the same core name as the reference product but must remain identifiable.

Immunization

Immunization Compounding Pharmacies FDA Hospitals

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

JUNE 17, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Mail-Order Pharmacies

Mail-Order Pharmacies Compounding Pharmacies Medical Records Dosage

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

JUNE 20, 2025

Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. This change mirrored a January 2025 FDA safety alert and label update that urged providers to consider genetic testing, inform patients of the risks, and discuss available options. NHS Press Release.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

JUNE 10, 2025

Meloxicam injection (Xifyrm; Azurity Pharmaceuticals, Inc) received FDA approval for use in adults for the management of moderate-to-severe pain, either alone or in combination with non-steroidal anti-inflammatory drug (NSAID) analgesics. Designing the ideal perioperative pain management plan starts with multimodal analgesia. August 24, 2018.

FDA

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization

How to help patients avoid food poisoning

The Checkup by Singlecare

AUGUST 7, 2025

When traveling, especially internationally, the CDC and FDA encourage people to consider these tips when visiting areas with unknown water quality: Drink bottled water (if bottled water isn’t available, boiling water for at least one minute is an effective way to kill germs). Pregnant women should also avoid high-risk foods.

Immunization

Immunization Labelling Chemotherapy Packaging

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Pharmacy Times

JULY 9, 2025

Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy.

Immunization

Immunization Compounding Pharmacies FDA Chemotherapy

Study Shows High-Dose Vitamin D Boosts Treatment Response in Breast Cancer

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy

Chemotherapy Immunization Compounding Pharmacies Hospitals

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding

Compounding Compounding Pharmacies Patient Care Immunization

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

JUNE 19, 2025

2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. In October 2024, CAR T therapy axicabtagene ciloleucel (Yescarta; Kite Pharma) received FDA regenerative medicine advanced therapy designation as a first-line treatment for high-risk large B-cell lymphoma. Accessed February 2025. March 6, 2025.

Compounding

Compounding Compounding Pharmacies FDA Immunization

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

JUNE 17, 2025

Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.

Dosage

Dosage Compounding Pharmacies Immunization Chemotherapy

From Med Rec to AI: Pharmacists Expanding Their Role in Oncology Innovation

Pharmacy Times

JULY 23, 2025

So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy. It frees up appointment slots for patients who need urgent care and helps streamline the process for new patients. Przespolewski : Pharmacists play a large role in managing drug shortages, especially those on the front lines.

Specialty Pharmacies

Specialty Pharmacies Hospitals Compounding Pharmacies Immunization

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. I know the FDA is very interested in using real-world data to help inform and confirm some of the benefits that we are seeing in trials. We look at ADCs. Unfortunately, these drugs are quite toxic.

Compounding Pharmacies

Compounding Pharmacies Immunization Hospitals Compounding

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!

Chemotherapy

Chemotherapy Packaging Communication Hospitals

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

JUNE 11, 2025

The FDA approved taletrectinib (Ibtrozi; Nuavtion Bio Inc) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC). It demonstrated high response rates with durable benefit and intracranial activity and was well-tolerated among patients, according to the FDA.

FDA

FDA Compounding Pharmacies Immunization Hospitals

NICE backs KEYTRUDA combination for advanced endometrial cancer

Pharma Times

AUGUST 7, 2025

Until now, only those with dMMR tumours had access to immunotherapy in combination with chemotherapy. Results from the KEYNOTE-868 / GY018 trial showed that combining pembrolizumab with chemotherapy led to longer progression-free survival compared to chemotherapy alone.

Chemotherapy

Chemotherapy FDA Hospitals

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

JUNE 9, 2025

Dalton shared her surprise about how variability in manufacturing affects the patient experience, given that some products created using the patient’s cells may not always be usable or up to FDA standards. 2 For Dyke’s team, balancing research and commercial pathways have created gray areas. REFERENCES 1. Cellular and Gene Therapy Products.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

Exploring Natural Compounds: Prunus Armeniaca, Bee Venom, and Bioactives in Breast Cancer Therapy

Pharmacy Times

AUGUST 12, 2025

Usual treatments like chemotherapy, hormone therapy, radiation, and surgery have undeniably helped patients live longer. SHOW MORE Natural compounds like prunus armeniaca and bee venom enhance breast cancer treatment, boosting efficacy and reducing side effects. Yet, these come with substantial adverse effects and, often, therapy resistance.

Compounding

Compounding Compounding Pharmacies Immunization Vaccines

Allopurinol alternatives: What can I take instead of allopurinol?

The Checkup by Singlecare

AUGUST 4, 2025

However, the Food and Drug Administration (FDA) warns on Uloric’s label that it may be associated with a higher risk of cardiovascular death compared to allopurinol. This occurs most commonly during chemotherapy. For that reason, it is avoided in the setting of heart disease or past myocardial infarction (heart attack).

Intravenous Solutions

Intravenous Solutions Insurance Chemotherapy FDA

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

JULY 1, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up for our daily news round-up!

Packaging

Packaging Chemotherapy Communication Hospitals

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Pharmacy Times

JULY 14, 2025

SHOW MORE FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care. The FDA has granted fast track designation to TRE-515 (Trethera Corporation), a novel drug, in combination with radiation therapy for the treatment of prostate cancer.

FDA

FDA Compounding Pharmacies Compounding Immunization

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Hospitals

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Specialty Pharmacies

FDA Expedites Durvalumab Review for Resectable Early-Stage Gastric, Gastroesophageal Cancers

What will shape the Pharma landscape in Q3 2025?

Trending Sources

Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use

With ADCs on the rise, drugmakers embrace a new oncology pillar

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

TAR-200 Clears Tumors in 82% of Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

The MEK effect on cancer — a slow and steady approach to drug resistance

Ondansetron (Zofran) alternatives: What can I take instead?

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacist’s Role Expands in the Era of Cannabis Rescheduling

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Zongertinib Approved by FDA for Patients With Nonsquamous NSCLC With HER2 TKD Mutations

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacies Need Strategies to Improve Health Care Access

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

How to help patients avoid food poisoning

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Study Shows High-Dose Vitamin D Boosts Treatment Response in Breast Cancer

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

From Med Rec to AI: Pharmacists Expanding Their Role in Oncology Innovation

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Big pharma braces for revenue headwinds as patent expiries loom

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

NICE backs KEYTRUDA combination for advanced endometrial cancer

Pharmacists Take the Lead on Advanced Therapeutics

Exploring Natural Compounds: Prunus Armeniaca, Bee Venom, and Bioactives in Breast Cancer Therapy

Allopurinol alternatives: What can I take instead of allopurinol?

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Stay Connected